(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 May 2012 (03.05.2012)

PCT

(10) International Publication Number
WO 2012/058480 A1

(51) International Patent Classification:
A61K 38/37 (2006.01) *A61P 7/04* (2006.01)
C07K 14/755 (2006.01)

(21) International Application Number:
PCT/US2011/058165

(22) International Filing Date:
27 October 2011 (27.10.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/407,402	27 October 2010 (27.10.2010)	US
61/467,894	25 March 2011 (25.03.2011)	US
61/502,476	29 June 2011 (29.06.2011)	US

(71) Applicants *(for all designated States except US)*: **BAXTER INTERNATIONAL INC.** [US/US]; One Baxter Parkway, Deerfield, IL 60015 (US). **BAXTER HEALTHCARE S.A.** [CH/CH]; Thurgauerstrasse 130, CH-8152 Glattpark (Opfikon) (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **STEINITZ, Katharina, Nora** [AT/AT]; Querweg 14, A-2500 Siegenfeld (AT). **WILHELMINA VAN HELDEN, Paula, Maria** [NL/NL]; Eimeren 54, NL-5235 DV Den Bosch (NL). **REIPERT, Birgit, Maria** [DE/DE]; Heinegasse 2, A-2232 Deutsch-Wagram (AT). **SCHWARZ, Hans-Peter** [AT/AT]; Weimarer Strasse 76, A-1180 Vienna (AT). **EHRLICH, Hartmut** [DE/DE]; Bienenweg 1, A-1170 Vienna (AT).

(74) Agent: **PARENT, Annette**; Morgan, Lewis & Bockius LLP, One Market, Spear Street Tower, San Francisco, CA 94105 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2012/058480 A1

(54) Title: FVIII PEPTIDES FOR IMMUNE TOLERANCE INDUCTION AND IMMUNODIAGNOSTICS

(57) Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII- specific $CD4^+$ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.